688520.SHG Sinocelltech Group Ltd
- Market cap
- CNY 15.3B
- P/E
- -
- P/B
- 22.45x
- ROE
- -115.5%
- Dividend yield
- 0.73%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688520.SHG undervalued?
Graham numberThe Graham number of Sinocelltech Group Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sinocelltech Group Ltd fundamental analysis
No fundamental analysis for Sinocelltech Group Ltd yet.
Sinocelltech Group Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sinocelltech Group Ltd
Sinocelltech Group Limited, a biopharmaceutical company, engages in the research, development, and production of recombinant proteins, antibody drugs, viral infections, and vaccines in China. The company offers Anjiayin, a third-generation recombinant coagulation factor VIII product for the treatment of hemophilia A; Anpingxi, an anti-CD20 monoclonal antibody for the treatment of CD20-positive diffuse large B-cell non-Hodgkin's lymphoma; Anjiarun, an adalimumab biosimilar fo…
Full company profileSinocelltech Group Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sinocelltech Group Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 98.1M | 5.99M | 2.95M | 2.64M | 328K | 134M | 1.02B | 1.89B | 2.51B | 1.56B | 1.32B |
| Gross Profit | 75.8M | 1.40M | -61.7K | -3.99M | -2.79M | 119M | 984M | 1.78B | 2.39B | 1.56B | 1.19B |
| Operating Income | -74.4M | -145M | -460M | -798M | -714M | -857M | -358M | 6.37M | 568M | -427M | -532M |
| EBITDA | 8.33M | -113M | -420M | -750M | -656M | -791M | -379M | -191M | 340M | -433M | -687M |
| Net Income | -12.1M | -141M | -453M | -795M | -713M | -867M | -519M | -396M | 112M | -553M | -731M |
| EPS | -0.03 | -0.37 | -1.19 | -2.09 | -1.74 | -1.99 | -1.19 | -0.89 | 0.24 | -1.29 | -1.56 |
| Balance Sheet | |||||||||||
| Total Assets | 422M | 487M | 540M | 808M | 1.66B | 1.37B | 2.74B | 2.72B | 3.28B | 3.82B | 3.96B |
| Total Liabilities | 341M | 319M | 564M | 773M | 1.08B | 1.60B | 2.98B | 3.32B | 3.15B | 3.70B | 3.32B |
| Shareholders' Equity | 83.4M | 175M | -22.4M | 36.3M | 591M | -227M | -237M | -599M | 141M | 128M | 633M |
| Cash & Short-term Investments | 42.2M | 60.9M | 6.91M | 164M | 950M | 349M | 972M | 293M | 315M | 770M | 770M |
| Total Debt | 126M | 126M | 116M | 337M | 581M | 1.08B | 1.66B | 2.75B | 2.02B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -40.3M | -93.3M | -88.0M | -485M | -537M | -863M | -428M | -381M | 125M | -276M | - |
| Capital Expenditure | 137M | 68.9M | 103M | 128M | 117M | 194M | 555M | 505M | 376M | 217M | 199M |
| Free Cash Flow | -177M | -162M | -191M | -613M | -655M | -1.06B | -983M | -889M | -251M | -492M | -623M |
| Ratios | |||||||||||
| ROE | -14.6% | -80.5% | - | -2,189.5% | -120.6% | - | - | - | 79.5% | -431.3% | -115.5% |
| ROA | -2.9% | -29.0% | -84.0% | -98.3% | -42.8% | -63.1% | -19.0% | -14.6% | 3.4% | -14.5% | -18.5% |
| Net Profit Margin | -12.4% | -2,357.5% | -15,387.3% | -30,122.1% | -217,117.8% | -645.0% | -50.7% | -21.0% | 4.5% | -35.5% | -55.5% |
| Debt to Equity | 1.51x | 0.72x | - | 9.29x | 0.98x | - | - | - | 14.36x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sinocelltech Group Ltd dividends
- Dividend yield
- 0.73%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 112M | 0.26 | - |
| 2024 | CNY 106M | 0.23 | 94.8% |
| 2023 | CNY 117M | 0.26 | - |
| 2022 | CNY 84.5M | 0.19 | - |
| 2021 | CNY 32.3M | 0.07 | - |
| 2020 | CNY 23.0M | 0.06 | - |
| 2019 | CNY 11.8M | 0.03 | - |
| 2018 | 6.20M | 0.02 | - |
| 2017 | 6.13M | 0.02 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Sinocelltech Group Ltd
- Insiders 78.78%
- Institutions 2.94%
- Public & others 18.29%
- Shares outstanding 470M
- Free float 125M
Sinocelltech Group Ltd company profile
- Company name
- Sinocelltech Group Ltd
- Ticker
- 688520.SHG
- ISIN
- CNE100003ZL3
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,200
- Fiscal year end
- December
- Address
- No. 31, Kechuang 7th Street, Beijing, China, 100176
- Phone
- 86 10 5862 8288
- Website
- sinocelltech.com
About Sinocelltech Group Ltd
Sinocelltech Group Limited, a biopharmaceutical company, engages in the research, development, and production of recombinant proteins, antibody drugs, viral infections, and vaccines in China. The company offers Anjiayin, a third-generation recombinant coagulation factor VIII product for the treatment of hemophilia A; Anpingxi, an anti-CD20 monoclonal antibody for the treatment of CD20-positive diffuse large B-cell non-Hodgkin's lymphoma; Anjiarun, an adalimumab biosimilar for the treatment of various autoimmune diseases; Anbezu, a bevacizumab biosimilar for the treatment of various solid tumors; SCTV01, a series of recombinant protein vaccines for multiple variants of the new coronavirus; Fenolimab, a recombinant humanized anti-PD-1 monoclonal antibody for the treatment of solid tumors; and SCT1000, a recombinant 14-valent human papillomavirus (HPV) virus-like particle vaccine for the prevention of various cancers. It also develops other clinical-stage products, including SCT650C for the treatment of plaque psoriasis, axial spondylarthritis, and other autoimmune diseases; SCTC21C for the treatment of CD38-positive blood cancers; SCTB35 for the treatment of diseases, such as CD20-positive B-cell non-Hodgkin's lymphoma; SCTB14 for immunotherapy of multiple solid tumors; SCTB41 for multiple solid tumor immunotherapy; SCTV02 to prevent respiratory diseases; SCTV04C to prevent herpes zoster; SCT520FF, an anti-angiogenic biopharmaceutical product; and SCTT11 for the treatment of thyroid eye disease. The company was founded in 2007 and is based in Beijing, China. Sinocelltech Group Limited operates as a subsidiary of Lhasa Aili Investment Consulting Co., Ltd.
Sinocelltech Group Ltd management
8- Dr. Liangzhi Xie Ph.D.Chairman of the Board & GM · born 1966
- Ms. Jie MaAccounting Supervisor & Financial Director · born 1972
- Dr. Yang WangDeputy GM & Director · born 1959
- Mr. Fanbin PanHead of Engineering Equipment Department · born 1978
- Mr. Li Ming TangDeputy GM, Secretary of the Board & Director · born 1980
- Ms. Yan Jing ZhangExecutive Director of Preclinical R&D Center · born 1975
- Ms. Chun Yun SunExecutive Director of Preclinical R&D Center · born 1976
- Ms. Chun Xia LuoPerson in charge of Pilot & Production Workshop · born 1971